You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Citation Tools

Article menu

Download PDFPDF

Rheumatology
Protocol
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Colomer-Carbonell A, Sanabria-Mazo JP, Hernández-Negrín H, et al
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
BMJ Open 2022;12:e055351. doi: 10.1136/bmjopen-2021-055351